

Global Internal and Collaboration Pipeline

Phase 1	Phase 2	Phase 3	Registration	Approved
Sonrotoclax BCL2 <ul style="list-style-type: none"> B-cell malignancies AML/MDS MM t(11;14) 	Zanubrutinib BTK <ul style="list-style-type: none"> B-cell lymphoma CD79B R/R DLBCL Lupus nephritis 	Zanubrutinib BTK <ul style="list-style-type: none"> TN MCL R/R MZL, R/R FL pMN 	Zanubrutinib BTK <ul style="list-style-type: none"> TN CLL/SLL (JP) R/R CLL/SLL (JP) R/R FL (CN) TN R/R WM (JP) 	Zanubrutinib BTK <ul style="list-style-type: none"> TN CLL/SLL (US, EU, CN, Others) R/R CLL/SLL (US, EU, Others) R/R CLL (CN) R/R MCL (US, CN, Others) R/R FL (US, EU, Others) R/R MZL (US, EU, Others) TN R/R WM (US, EU, CN, Others)
BGB-16673 BTK CDAC <ul style="list-style-type: none"> B-cell malignancies 	Sonrotoclax BCL2 <ul style="list-style-type: none"> R/R MCL R/R CLL R/R WM 	Sonrotoclax BCL2 <ul style="list-style-type: none"> TN CLL 	Tislelizumab PD1 <ul style="list-style-type: none"> Neo/adj NSCLC* 1L UBC LA ESCC R/R cHL 	Tislelizumab PD1 <ul style="list-style-type: none"> 1L NSCLC (EU) 2/3L NSCLC (EU) 1L Sq. NSCLC (EU) 1L ES-SCLC (CN) 1L GC/GEJC (ITT-US, CN) 1L ESCC (US, EU) 2L ESCC (US)
BGB-21447 next gen BCL2 <ul style="list-style-type: none"> B-cell malignancies 	Ociperlimab TIGIT <ul style="list-style-type: none"> 1L NSCLC 	Tislelizumab PD1 <ul style="list-style-type: none"> 1L NSCLC PDL1-high 	Pamiparib PARP <ul style="list-style-type: none"> 2L MTx gBRCAm PSOC 	Tislelizumab PD1 <ul style="list-style-type: none"> 1L Non-sq. NSCLC (CN) 1L Sq. NSCLC (CN) 2/3L NSCLC (CN) 1L GC (CN) 1L HCC (CN) 2/3L HCC (CN) 1L ESCC (CN) 2L ESCC (EU, CN) 2L UBC (CN) 1L NPC (CN) 2L MSI-H/dMMR (CN) R/R cHL (CN)
BGB-A445 OX40 <ul style="list-style-type: none"> Solid tumors 	LBL-007³ LAG3 <ul style="list-style-type: none"> MSS-CRC 1L ESCC 	Pamiparib PARP <ul style="list-style-type: none"> 2L MTx gBRCAm PSOC 	Ociperlimab TIGIT <ul style="list-style-type: none"> 1L NSCLC PDL1-high 	Pamiparib PARP <ul style="list-style-type: none"> 2L gBRCAm OC (CN)
Surzebiclimab TIM3 <ul style="list-style-type: none"> Solid tumors 	BGB-A445 OX40 <ul style="list-style-type: none"> Melanoma, RCC, UC 	Zanidatamab¹ HER2 BsAb <ul style="list-style-type: none"> 1L HER2+ GEA 	Zanidatamab¹ HER2 BsAb <ul style="list-style-type: none"> 1L HER2+ GEA 	
BGB-15025 / 26808 HPK1 <ul style="list-style-type: none"> 15025- Solid tumors 26808- Solid tumors 	Umbrella Studies Multiple <ul style="list-style-type: none"> 1L NSCLC 2L+ NSCLC Neoadj NSCLC 1L HNSCC 	Tarlatamab² DLL3 x CD3 <ul style="list-style-type: none"> 20210004 2L SCLC 		
BGB-30813 DGKζ <ul style="list-style-type: none"> Solid tumors 	Zanidatamab¹ HER2 BsAb <ul style="list-style-type: none"> HER2+ 2L BTC 			
BGB-A3055 CCR8 <ul style="list-style-type: none"> Solid tumors 				
BGB-24714 SMAC mimetic <ul style="list-style-type: none"> Solid tumors 				
BGB-10188 PI3Kδ <ul style="list-style-type: none"> Solid tumors 				
BGB-43395 CDK4 <ul style="list-style-type: none"> BC & Solid tumors 				
Zanidatamab¹ HER2 BsAb <ul style="list-style-type: none"> 1L mBC/GC 				
Xaluritamig² STEAP1 x CD3 <ul style="list-style-type: none"> 20180146 mCRPC (initiation activities) 				

● Heme ● Solid tumors ● Non-Oncology

Registration includes select accepted submissions

* Primary endpoint met; CN = China

- Zymeworks/Jazz collaboration, BeiGene has APAC/ex Japan, AU, NZ commercial rights
- Amgen collaboration, BeiGene will have China commercial rights and tiered mid-single digit royalties on net sales outside of China. "Initiation activities" refers to clinical activities, approval is obtained to initiate the study in China.
- Leads Biolabs collaboration, BeiGene has ex-China commercial rights